A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease

References

• Cabot RC, Castleman B, Towne VW. CASE records of the Massachusetts general hospital weekly clinicopathological exercises: case 40011. N Engl J Med. 1954;250:26–30.
   PubMedGoogle Scholar
• Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–30.
   PubMed Web of Science ®Google Scholar
• Frizzera G, Banks PM, Massarelli G, Rosai J. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol. 1983;7:211–31.
   PubMed Web of Science ®Google Scholar
• Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004;43(8):698–704.
   PubMed Web of Science ®Google Scholar
• Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128(8):657–62.
   PubMed Web of Science ®Google Scholar
• Talat N, Schulte KM. Castleman's disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16(9):1316–24.
   PubMed Web of Science ®Google Scholar
• Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, et al. Clinical features and treatment of multicentric Castleman's disease: a retrospective study of 21 Japanese patients at a Single Institute. J Clin Exp Hematopathol. 2013;53(1):69–77.
   PubMedGoogle Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74(4):1360–7.
   PubMed Web of Science ®Google Scholar
• Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine. 2002;20(6):304–11.
   PubMed Web of Science ®Google Scholar
• Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406–12.
   PubMed Web of Science ®Google Scholar
• Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16(4):236–46.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123(19):2924–33.
   PubMed Web of Science ®Google Scholar
• Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg. 2012;255(4):677–84.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010;28(23):3701–8.
   PubMed Web of Science ®Google Scholar
• Yoshizaki K, Murayama S, Ito H, Koga T. The Role of Interleukin-6 in Castleman Disease. Hematol Oncol Clin North Am. 2018;32(1):23–36.
   PubMed Web of Science ®Google Scholar
• Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, et al. Interleukin-6 gene expression in Castleman's disease. Blood. 1991;78(11):2923–30.
   PubMed Web of Science ®Google Scholar
• Iwaki N, Gion Y, Kondo E, Kawano M, Masunari T, Moro H, et al. Elevated serum interferon gamma-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep. 2017;7:42316.
   PubMed Web of Science ®Google Scholar
• Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, et al. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia–a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop. 2013;53(1):79–85.
   PubMedGoogle Scholar
• Gherardi RK, Belec L, Fromont G, Divine M, Malapert D, Gaulard P, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood. 1994;83(9):2587–93.
   PubMed Web of Science ®Google Scholar
• Lee M, Hirokawa M, Matuoka S, Hasegawa H, Nanjo H, Matsushima T, et al. Multicentric Castleman's disease with an increased serum level of macrophage colony-stimulating factor. Am J Hematol. 1997;54(4):321–3.
   PubMed Web of Science ®Google Scholar
• Nishi J, Arimura K, Utsunomiya A, Yonezawa S, Kawakami K, Maeno N, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol. 1999;104(3):482–5.
   PubMed Web of Science ®Google Scholar
• Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. JCO. 1985;3(9):1202–16.
   PubMed Web of Science ®Google Scholar
• Lachant NA, Sun NC, Leong LA, Oseas RS, Prince HE. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol. 1985;83(1):27–33.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castleman's disease. Am J Hematol. 2012;87(11):997–1002.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Koga T, Kawakami A, Kawabata H, Okamoto S, Mizuki M, et al. Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan. Mod Rheumatol. 2018;28(1):161–7.
   PubMed Web of Science ®Google Scholar
• Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.
   PubMed Web of Science ®Google Scholar
• Foussat A, Fior R, Girard T, Boue F, Wijdenes J, Galanaud P, et al. Involvement of human interleukin-6 in systemic manifestations of human herpesvirus type 8-associated multicentric Castleman's disease. AIDS. 1999;13(1):150–2.
   PubMed Web of Science ®Google Scholar
• Chen KT. Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol. 1984;8(4):287–93.
   PubMed Web of Science ®Google Scholar
• Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116(18):3627–34.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–74.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95(1):56–61.
   PubMed Web of Science ®Google Scholar
• Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91(2):220–6.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93.
   PubMed Web of Science ®Google Scholar
• Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23(18):3151–71.
   PubMed Web of Science ®Google Scholar